Specifically, in the latter study, the administration of ZYC300, a DNA plasmid encoding the tumour-associated carcinogen activator cytochrome P450 1B1 (CYP1B1) [208], was used to treat 17 patients with advanced-stage progressive cancer and led to CYP1B1 immunity induction and marked response to next regimen in six of them [209]. Here, CYP1B1 is linked to cancer.